Business
GLUCOTRACK ANNOUNCES POSTER PRESENTATION ON CONTINUOUS BLOOD GLUCOSE MONITOR SURVEY DATA AT THE ASSOCIATION OF DIABETES CARE AND EDUCATION SPECIALISTS (ADCES) 2024 ANNUAL CONFERENCE
Market research data shows interest in additional glucose monitoring options for people with diabetes who use insulin Rutherford, NJ, Aug. 05, 2024 (GLOBE
About this update from Glucotrack, Inc.
[{"type":"text","content":"Market research data shows interest in additional glucose monitoring options for people with diabetes who use insulin Rutherford, NJ, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that an emerging science industry poster will be presented at the Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference to be held August 9-12, 2024 in New Orleans, LA. The Glucotrack poster will present market research data on the acceptance of the Company’s Continuous Blood Glucose Monitor (CBGM) concept among people with type 1 and type 2 diabetes. “We look forward to sharing our findings on our continuous blood glucose monitor with the diabetes care community at ADCES,” said Paul V. Goode, PhD, CEO of Glucotrack. “This data contributes to the growing body of evidence demonstrating the need for and growing interest in expanding glucose monitoring options.” The poster will be made available on the Glucotrack website following the poster session at the conference. Presentation details are as follows; times noted are Eastern time: Poster Title: Evaluating Acceptance of a Continuous Blood Glucose Monitor for Insulin-Requiring People with DiabetesPoster Session Date / Time: Saturday, August 10, 12:15 PM - 1:15 PM For more information about Glucotrack’s CBGM, visit glucotrack.com. # # # About Glucotrack, Inc. Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes. Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 2+ years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com. Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. With...